A5005070167- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Hepatitis B Virus Studies
- Inhalation and Respiratory Drug Delivery
- vaccines and immunoinformatics approaches
- Virus-based gene therapy research
- COVID-19 Clinical Research Studies
- CAR-T cell therapy research
- COVID-19 and healthcare impacts
- Animal Virus Infections Studies
- Immunodeficiency and Autoimmune Disorders
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Viral Infectious Diseases and Gene Expression in Insects
- Immune responses and vaccinations
- Neuroblastoma Research and Treatments
- Cystic Fibrosis Research Advances
- Vaccine Coverage and Hesitancy
- NF-κB Signaling Pathways
- Cytokine Signaling Pathways and Interactions
- Multiple Sclerosis Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Pharmaceutical studies and practices
NIHR CRUK Experimental Cancer Medicine Centre
2021-2022
University of Southampton
2018-2022
Cancer Research UK
2021-2022
Southampton General Hospital
2021-2022
Sears Holdings (United States)
2007
Abstract Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights these studies have been intrinsic limitations in study design. Here we present PROSECO prospective observational ( NCT04858568 ) on 457 patients lymphoma that received two or three vaccine doses. We show undetectable humoral responses following doses 52% undergoing active anticancer treatment. Moreover, 60% anti-CD20 therapy had antibodies...
Abstract Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies 1–3 . Although studies mouse models solid tumours demonstrated PI3Kδ (PI3Kδi) can induce anti-tumour immunity 4,5 , its effect on humans remains unclear. Here we assessed the effects PI3Kδi AMG319 human patients with head neck cancer neoadjuvant, double-blind, placebo-controlled randomized phase II trial (EudraCT no....
6068 Background: AMG319 is a PI3Kδ inhibitor. Preclinically, target inhibition abrogates Treg mediated immunosuppression, augmenting CD8+ T-cell anti-tumour activity. This study aims to quantify the immunological effects of on tumour microenvironment in HNSCC patients (pts). Methods: The trial neoadjuvant window 54 pts, randomised 2:1 AMG319/placebo for 20-29 days. Eligible pts have operable HNSCC, ECOG 0/1, adequate organ function and no active autoimmune disease. Primary endpoints are...
<title>Abstract</title> Phosphoinositide 3-kinase δ (PI3Kδ) plays a key role in lymphocytes and inhibitors targeting this PI3K have been approved for hematological malignancies. While studies solid tumor models mice demonstrated that PI3Kδ (PI3Kδi) can induce anti-tumor immunity, the impact of PI3Kδi on tumors humans remains unclear. Here, we assessed effects AMG319 patients with resectable head neck cancer neoadjuvant, double-blind, placebo-controlled randomised phase-II trial. We find...
SUMMARY SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell responses the spike domain can be used to measure vaccine immune response. Individuals with lymphoma have defects in humoral cellular immunity that may compromise In this prospective observational study of 457 participants lymphoma, 52% vaccinated on treatment had undetectable anti-spike IgG antibodies compared 9% who were not treatment. Marked impairment was observed those receiving anti- CD20...
Previous studies have shown that an agonist of the peroxisome proliferator activated receptor gamma (PPARg) is currently used to treat type 2 diabetes, also shows anti-inflammatory effects in T-cells and glial cells; improves metabolism; neuroprotective. In mouse models multiple sclerosis, PPARg agonists were reduce disease severity, a case report Actos (pioglitazone) was be well tolerated secondary progressive MS patient. view its good safety profile, we carried out one-year,...